Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

NCT02933866

Scalp Psoriasis

COMPLETED PHASE3

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

NCT02985736

Psoriasis

COMPLETED PHASE4

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

NCT05896527

Plaque Psoriasis

COMPLETED PHASE2

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

NCT00881868

Scalp Psoriasis

COMPLETED PHASE4

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

NCT01206387

Psoriasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriasis is a non-contagious skin disorder affecting up to 2% of the world population. It is estimated that 26 million people in the U.S. and Europe suffer from psoriasis. Forty percent (40%) of these suffer from psoriasis of the scalp. Currently, there are three primary modalities for the treatment of psoriasis: topical, phototherapy and systemic treatments. While existing treatments provide varying degrees of relief for this illness, they do not provide a long-term cure. Additionally, there is evidence that some of these existing treatments may cause significant side effect. The purpose of this study is to demonstrate that DermiPsor's DPS-102 (test product) is statistically more effective for the treatment of psoriasis current topical treatment options. It is also intended to assess the safety of DPS-102.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

DPS-102

Group Type EXPERIMENTAL

DPS-102

Intervention Type DRUG

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

2

Vehicle

Group Type PLACEBO_COMPARATOR

Vehicle / Placebo

Intervention Type OTHER

The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

3

Calcipotriol Monotherapy

Group Type ACTIVE_COMPARATOR

Calcipotriol Monotherapy

Intervention Type DRUG

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

4

Nicotinamide Monotherapy

Group Type ACTIVE_COMPARATOR

Nicotinamide Monotherapy

Intervention Type DRUG

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DPS-102

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention Type DRUG

Vehicle / Placebo

The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention Type OTHER

Calcipotriol Monotherapy

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention Type DRUG

Nicotinamide Monotherapy

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female of age 18 or older
* Patient with a personal history of scalp psoriasis
* Patient with treatable lesions
* Patient with a TSS score equal or lower than 9.
* Patient with a PGA score equal or lower than 5.
* Patient with a negative urine pregnancy test at inclusion for women of childbearing potential and using an efficient contraceptive (oral contraceptives, IUD, or tubal ligation)
* Patient agreeing to participate to the study and to sign a written informed consent and comply with study requirements.

Exclusion Criteria

* Patient treated with topical scalp treatment for scalp psoriasis within two weeks prior to the inclusion in the study (corticoids, retinoids, vitamin D derivatives),
* Patient treated with systemic treatment for psoriasis (biologics, methotrexate, cyclosporine, retinoids) within one month prior to the inclusion in the study
* Patient taking systemic niacin or multivitamins within past two weeks
* Patient who start or modify a treatment with beta-blockers within one month prior to the inclusion in the study
* Patient with PEG (Poly Ethylene Glycol) allergy
* Pregnant or breast feeding female or female who do not use contraception,
* Patient with an history of hypersensitivity to Dovonex/Daivonex
* Patient who has participated in a clinical trial within three month prior inclusion,
* Patients on Carbamazepine and Primidione (the clearance of Primidione and Carbamazepine may be reduced with the concomitant use of Nicotinamide)
* Patient who is under guardianship, or unable to understand the information (for linguistic or mental reason), or unwilling to give her/his informed consent to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No